医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata Selected by ASLAN Pharmaceuticals as Enterprise-Wide Technology Platform for Enhancing Clinical Development

2014年10月31日 AM06:30
このエントリーをはてなブックマークに追加


 

NEW YORK

Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it has signed an enterprise agreement with ASLAN Pharmaceuticals, an oncology-focused biotechnology company. ASLAN’s adoption of the industry-leading Medidata Clinical Cloud™ supports the company’s strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development in Asia.

“ASLAN is committed to transforming drug development paradigms and fundamentally changing the way serious illnesses are treated,” said Dr. Mark McHale, COO of ASLAN. “We selected the Medidata Clinical Cloud as our enterprise-wide technology platform because it is helping us bring greater speed and efficiency to clinical trials. With its broad adoption across Asia, the Medidata platform allows us to be more creative, agile and efficient, while ensuring investigator engagement in our studies.”

With offices in Singapore and Taiwan, ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies and leverages high-quality, innovative clinical centers in Asia to advance drug development. In support of this work, ASLAN is using Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and randomization and supply management (Medidata Balance®).

“We’re thrilled ASLAN is using the Medidata platform to conduct early clinical studies in areas of significant unmet need,” said Glen de Vries, Medidata’s president. “We share ASLAN’s vision of transforming clinical development, so that innovative new medicines can be delivered to patients faster and with lower cost and risk.”

Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region, said, “The life science industry is growing in APAC, allowing for more and more business opportunities. I am honored that Medidata’s technology is helping this emerging market execute better trials to produce innovative drugs for the rest of the world.”

Connect with Medidata:

About ASLAN

ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of high-value, differentiated clinical programs. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Asia with a platform which reaches across the region via its offices in Singapore and Taiwan, enabling the Company to conduct and support regional clinical development programs. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN001, the Company’s lead program, is entering phase 2b for gastric cancer. For more information, please visit www.aslanpharma.com.

About Medidata Solutions

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

CONTACT

Media:
Medidata Solutions
Masako Ishida, +81 3 4588 0400
mishida@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作